Biotech firms fill gap in antibiotic-drug development

08/15/2013 | Genetic Engineering & Biotechnology News

With large drugmakers abandoning the antibiotics market, a number of small to medium biopharmaceutical firms are stepping up to develop novel and more effective antibiotics against drug-resistant bacteria, according to this article. For example, Cubist Pharmaceuticals has several antibiotics in late-stage development, including CXA-201, a combination of ceftolozane and tazobactam. Achaogen is planning a late-stage study of plazomicin against carbapenem-resistant enterobacteriaceae.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC